Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2009

01.09.2009 | Review

Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs

verfasst von: Beata Zahorowska, Philip J. Crowe, Jia-Lin Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Targeted therapy refers to anticancer treatment which specifically targets key molecules of cancer cells and/or neovascular cells, aiming to thus interfere with processes of tumorigenesis, cancer progression and metastasis. The epidermal growth factor receptor (EGFR) was the first receptor to be proposed for targeted cancer therapy, having been found to be commonly overexpressed in a range of solid tumors and play a role in cancer cell proliferation, apoptosis, angiogenesis, invasion and metastasis. Despite successful development of EGFR-targeted pharmacological agents, clinical and molecular studies have indicated several limitations to the broad application of this treatment as a monotherapy. Novel combination treatments which might optimize the effect of EGFR inhibition have, therefore, been investigated. Research conducted into the mechanisms of action and synergy of these combination treatments is likely to enhance the role of the EGFR target in future cancer treatment.
Literatur
Zurück zum Zitat Amann J, Kalyankrishna S, Masson PP et al (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1):226–235PubMed Amann J, Kalyankrishna S, Masson PP et al (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1):226–235PubMed
Zurück zum Zitat Ariyama H, Qin B, Baba E et al (2006) Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97(4):724–734. doi:10.1002/jcb.20678 PubMedCrossRef Ariyama H, Qin B, Baba E et al (2006) Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97(4):724–734. doi:10.​1002/​jcb.​20678 PubMedCrossRef
Zurück zum Zitat Boccellino M, Giuberti G, Quagliuolo L et al (2004) Apoptosis induced by interferon-α and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol 201(1):73–83. doi:10.1002/jcp.20058 CrossRef Boccellino M, Giuberti G, Quagliuolo L et al (2004) Apoptosis induced by interferon-α and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol 201(1):73–83. doi:10.​1002/​jcp.​20058 CrossRef
Zurück zum Zitat Bruzzese F, Di Gennaro E, Avallone A et al (2006) Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12(2):617–625. doi:10.1158/1078-0432.CCR-05-1671 PubMedCrossRef Bruzzese F, Di Gennaro E, Avallone A et al (2006) Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12(2):617–625. doi:10.​1158/​1078-0432.​CCR-05-1671 PubMedCrossRef
Zurück zum Zitat Buck E, Eyzaguirre A, Brown E et al (2006a) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon and breast tumors. Mol Cancer Ther 5(11):2676–2684. doi:10.1158/1535-7163.MCT-06-0166 PubMedCrossRef Buck E, Eyzaguirre A, Brown E et al (2006a) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon and breast tumors. Mol Cancer Ther 5(11):2676–2684. doi:10.​1158/​1535-7163.​MCT-06-0166 PubMedCrossRef
Zurück zum Zitat Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK (2006b) Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5(8):2051–2059. doi:10.1158/1535-7163.MCT-06-0007 PubMedCrossRef Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK (2006b) Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5(8):2051–2059. doi:10.​1158/​1535-7163.​MCT-06-0007 PubMedCrossRef
Zurück zum Zitat Caraglia M, Tagliaferri P, Marra M et al (2003) EGF activates an inducible survival response via the RAS-> ERK-1/2 pathway to counteract interferon-α mediated apoptosis in epidermoid cancer cells. Cell Death Differ 10(2):218–229. doi:10.1038/sj.cdd.4401131 PubMedCrossRef Caraglia M, Tagliaferri P, Marra M et al (2003) EGF activates an inducible survival response via the RAS-> ERK-1/2 pathway to counteract interferon-α mediated apoptosis in epidermoid cancer cells. Cell Death Differ 10(2):218–229. doi:10.​1038/​sj.​cdd.​4401131 PubMedCrossRef
Zurück zum Zitat Caraglia M, Marra M, Viscomi C et al (2007) The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways. Int J Cancer 121:2317–2330. doi:10.1002/ijc.22964 PubMedCrossRef Caraglia M, Marra M, Viscomi C et al (2007) The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways. Int J Cancer 121:2317–2330. doi:10.​1002/​ijc.​22964 PubMedCrossRef
Zurück zum Zitat Chada KC, Ambrus JL Jr, Dembinski W, Ambrus JL Sr (2004) Interferons and interferon inhibitory activity in disease and therapy. Exp Biol Med 229:285–290 Chada KC, Ambrus JL Jr, Dembinski W, Ambrus JL Sr (2004) Interferons and interferon inhibitory activity in disease and therapy. Exp Biol Med 229:285–290
Zurück zum Zitat Ciardiello F, Troiani T, Bianco R et al (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17:109–114. doi:10.1093/annonc/mdl962 CrossRef Ciardiello F, Troiani T, Bianco R et al (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17:109–114. doi:10.​1093/​annonc/​mdl962 CrossRef
Zurück zum Zitat Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ et al (2006) Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119(11):2557–2566. doi:10.1002/ijc.22221 PubMedCrossRef Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ et al (2006) Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119(11):2557–2566. doi:10.​1002/​ijc.​22221 PubMedCrossRef
Zurück zum Zitat Douillard J-Y, Kim E, Hirsch V et al (2007) Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2(8 Suppl 4):305 (PPS-02)CrossRef Douillard J-Y, Kim E, Hirsch V et al (2007) Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2(8 Suppl 4):305 (PPS-02)CrossRef
Zurück zum Zitat Dowlati A, Nethery D, Kern JA (2004) Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 3(4):459–463PubMed Dowlati A, Nethery D, Kern JA (2004) Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 3(4):459–463PubMed
Zurück zum Zitat Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ et al (2009) Phase I study of bortezomib and cetuximab in patients with solid tumors expressing epidermal growth factor receptor. Br J Cancer 100:1379–1384. doi:10.1038/sj.bjc.6605043 PubMedCrossRef Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ et al (2009) Phase I study of bortezomib and cetuximab in patients with solid tumors expressing epidermal growth factor receptor. Br J Cancer 100:1379–1384. doi:10.​1038/​sj.​bjc.​6605043 PubMedCrossRef
Zurück zum Zitat Herbst RS, Fehrenbacher L, Belani CP et al (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743–4750. doi:10.1200/JCO.2007.12.3026 PubMedCrossRef Herbst RS, Fehrenbacher L, Belani CP et al (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743–4750. doi:10.​1200/​JCO.​2007.​12.​3026 PubMedCrossRef
Zurück zum Zitat Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64(15):5355–5362. doi:10.1158/0008-5472.CAN-04-0562 PubMedCrossRef Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64(15):5355–5362. doi:10.​1158/​0008-5472.​CAN-04-0562 PubMedCrossRef
Zurück zum Zitat Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K (2005) Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-α in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745(3):401–410. doi:10.1016/j.bbamcr.2005.06.003 PubMedCrossRef Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K (2005) Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-α in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745(3):401–410. doi:10.​1016/​j.​bbamcr.​2005.​06.​003 PubMedCrossRef
Zurück zum Zitat Ishitsuka K, Hideshima T, Neri P et al (2008) p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple-myeloma; therapeutic implications. Br J Haematol. doi:10.1111/j.1365-2141.2008.07044.x Ishitsuka K, Hideshima T, Neri P et al (2008) p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple-myeloma; therapeutic implications. Br J Haematol. doi:10.​1111/​j.​1365-2141.​2008.​07044.​x
Zurück zum Zitat Jung YD, Mansfield PF, Akagi M et al (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133–1140. doi:10.1016/S0959-8049(02)00013-8 PubMedCrossRef Jung YD, Mansfield PF, Akagi M et al (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133–1140. doi:10.​1016/​S0959-8049(02)00013-8 PubMedCrossRef
Zurück zum Zitat Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG (2009) Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 8(4):821–833. doi:10.1158/1535-7163.MCT-09-0058 PubMedCrossRef Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG (2009) Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 8(4):821–833. doi:10.​1158/​1535-7163.​MCT-09-0058 PubMedCrossRef
Zurück zum Zitat Linardou H, Dahabreh I, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972. doi:10.1016/S1470-2045(08)70206-7 PubMedCrossRef Linardou H, Dahabreh I, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972. doi:10.​1016/​S1470-2045(08)70206-7 PubMedCrossRef
Zurück zum Zitat Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK, Perez-Soler R (2007) Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72(2):248–258. doi:10.1124/mol.107.034827 PubMedCrossRef Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK, Perez-Soler R (2007) Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72(2):248–258. doi:10.​1124/​mol.​107.​034827 PubMedCrossRef
Zurück zum Zitat Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. doi:10.1056/NEJMoa040938 PubMedCrossRef Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. doi:10.​1056/​NEJMoa040938 PubMedCrossRef
Zurück zum Zitat Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer. J Clin Oncol 26:4233–4235. doi:10.1200/JCO.2007.15.0185 CrossRef Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer. J Clin Oncol 26:4233–4235. doi:10.​1200/​JCO.​2007.​15.​0185 CrossRef
Zurück zum Zitat Matar P, Rojo F, Cassia R et al (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10(19):6487–6501. doi:10.1158/1078-0432.CCR-04-0870 PubMedCrossRef Matar P, Rojo F, Cassia R et al (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10(19):6487–6501. doi:10.​1158/​1078-0432.​CCR-04-0870 PubMedCrossRef
Zurück zum Zitat Matsubara J, Yamada Y, Nakajima TE et al (2008) Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74(1–2):76–83. doi:10.1159/000139127 PubMedCrossRef Matsubara J, Yamada Y, Nakajima TE et al (2008) Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74(1–2):76–83. doi:10.​1159/​000139127 PubMedCrossRef
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525 PubMedCrossRef Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966. doi:10.​1200/​JCO.​2006.​07.​9525 PubMedCrossRef
Zurück zum Zitat Morgillo F, Kim WY, Kim EW, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-1R pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13(9):2795–2803. doi:10.1158/1078-0432.CCR-06-2077 PubMedCrossRef Morgillo F, Kim WY, Kim EW, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-1R pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13(9):2795–2803. doi:10.​1158/​1078-0432.​CCR-06-2077 PubMedCrossRef
Zurück zum Zitat Niho S, Ichinose Y, Tamura T et al (2007) Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimes. ASCO annual meeting proceedings Part 1. J Clin Oncol 25(18S) (LBA7509) Niho S, Ichinose Y, Tamura T et al (2007) Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimes. ASCO annual meeting proceedings Part 1. J Clin Oncol 25(18S) (LBA7509)
Zurück zum Zitat Pao W, Miller VA, Politi KA et al (2005a) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):0225–0235CrossRef Pao W, Miller VA, Politi KA et al (2005a) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):0225–0235CrossRef
Zurück zum Zitat Pao W, Wang TY, Riely GJ et al (2005b) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib. PLoS Med 2(1):0057–0061CrossRef Pao W, Wang TY, Riely GJ et al (2005b) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib. PLoS Med 2(1):0057–0061CrossRef
Zurück zum Zitat Raja SM, Clubb RJ, Bhattacharyya M et al (2008) A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependant ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 7(10):1630–1640PubMedCrossRef Raja SM, Clubb RJ, Bhattacharyya M et al (2008) A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependant ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 7(10):1630–1640PubMedCrossRef
Zurück zum Zitat Saltz L (2008) Colorectal cancer treatment: what’s next? (or: is there life after EGFR and VEGF?). Gastrointest Cancer Res 2(Suppl 2):S20–S22PubMed Saltz L (2008) Colorectal cancer treatment: what’s next? (or: is there life after EGFR and VEGF?). Gastrointest Cancer Res 2(Suppl 2):S20–S22PubMed
Zurück zum Zitat Schaefer G, Shao L, Totpal K, Akita RW (2007) Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 67(3):1228–1238. doi:10.1158/0008-5472.CAN-06-3493 PubMedCrossRef Schaefer G, Shao L, Totpal K, Akita RW (2007) Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 67(3):1228–1238. doi:10.​1158/​0008-5472.​CAN-06-3493 PubMedCrossRef
Zurück zum Zitat Thyrell L, Hjortsberg L, Arulampalam V et al (2004) Interferon-α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279(23):24152–24162. doi:10.1074/jbc.M312219200 PubMedCrossRef Thyrell L, Hjortsberg L, Arulampalam V et al (2004) Interferon-α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279(23):24152–24162. doi:10.​1074/​jbc.​M312219200 PubMedCrossRef
Zurück zum Zitat Yang JL, Qu XJ, Russell PJ, Goldstein D (2005a) Interferon-α promotes the anti-proliferative effect of gefitinib (ZD1839) on human colon cancer cell lines. Oncology 69(3):224–238. doi:10.1159/000088070 PubMedCrossRef Yang JL, Qu XJ, Russell PJ, Goldstein D (2005a) Interferon-α promotes the anti-proliferative effect of gefitinib (ZD1839) on human colon cancer cell lines. Oncology 69(3):224–238. doi:10.​1159/​000088070 PubMedCrossRef
Metadaten
Titel
Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
verfasst von
Beata Zahorowska
Philip J. Crowe
Jia-Lin Yang
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0622-4

Weitere Artikel der Ausgabe 9/2009

Journal of Cancer Research and Clinical Oncology 9/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.